Phase 4 N=1,132 Study to Compare Ferric Carboxymaltose With Placebo in Patients With Acute Heart Failure and Iron Deficiency
Iron Deficiency · Heart Failure
Primary: HF Hospitalizations and CV Death — 293; 372; 274; 363 Events — p=0.059
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=347 Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure
Type 2 Diabetes Mellitus · Heart Failure
Primary: Change From Baseline in Left Ventricular End Diastolic Volume (LVEDV) Index Measured by Magnetic Resonance Imaging (MRI) at 24 Weeks — -3.395; -0.716 mL/m^2 — p=0.252
Phase 4 N=200 Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity
Obesity
Primary: Change in Body Weight — -7.69; -4.19 Percent change of body weight — p=<0.001
Phase 4 N=181 To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer
BRCA or HRR+ Mutated Ovarian Cancer Patients
Primary: Progression-Free Survival (PFS) — 18.0; 16.6 months
Phase 4 N=161 Rate Control Therapy Evaluation in Permanent Atrial Fibrillation (RATE-AF)
Permanent Atrial Fibrillation
Primary: Patient Reported Quality of Life (SF-36) — 29.7; 31.9 score on a scale
Phase 4 N=84 Compare Fentanyl Nasal Spray With Intravenous Opioids to Treat Severe Pain
Advanced Cancers · Pain
Primary: Non-inferiority of Fentanyl Nasal Spray Versus Intravenous Opioids in the Change in the Numeric Rating Scale (NRS) Pain Intensity Score at One Hour, Starting From the…
Phase 4 N=138 Immunogenicity Assessment of Peg-filgrastim vs. Neulasta® as Adjunct to Chemotherapy in Patients With Breast Cancer
Breast Cancer
Primary: Comparison of Cumulative Incidence of Anti-pegfilgrastim Antibodies (Binding and Neutralizing) to Pegfilgrastim Between Treatment Groups at the End of Cycle 4 (Day 84)…
Phase 4 N=70 Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia
Schizophrenia · Schizoaffective Disorder
Primary: Negative Symptoms as Measured by the Scale for the Assessment of Negative Symptoms (SANS) Total Score — 33.1; 34.1; 34.1; 32.8 score on a scale
Phase 4 N=43 The Effect of Lumify™ Eyedrops on Eyelid Position
Eyelid Droop
Primary: Palpebral Fissure Height — 9.64; 9.66; 9.92; 9.96 milimeter
Phase 4 N=21 Pharmacokinetics of Alglucosidase Alfa in Patients With Pompe Disease
Pompe Disease · Glycogen Storage Disease Type II (GSD II)
Primary: Pharmacokinetics (PK): Maximum Observed Plasma Concentration (Cmax) of Alglucosidase Alfa — 204000; 307000 nanograms per milliliter (ng/mL)
Phase 4 N=34 Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.
Neoplasms
Primary: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 6; 9; 1; 4 Participants
Phase 4 N=11 Hypothyroidism Treated With Calcitonin
Hypothyroidism
Primary: Modified City of Hope Quality of Life Questionnaire for Patients With Thyroid Disease — -36.33 score on a scale
Phase 4 N=11 Is Treatment of Vitamin D Deficiency Associated With Resolution of Statin-Induced Muscular Symptoms
Myopathic Symptoms
Primary: Number of Participants With Reduction in Myopathic Pain — 4; 4 Participants
Phase 4 N=1,561 MAST Trial: Multi-modal Analgesic Strategies in Trauma
Nonspecific Pain Post Traumatic Injury
Primary: Opioid Use Per Day — 48; 34 MME per day
Phase 4 N=48 VAccination to Improve Clinical outComes in Heart Failure Trial: a Feasibility Study (VACC-HeFT)
Chronic Heart Failure
Primary: Number of Participants With 4 Fold Rise in Serum Antibody Concentration of A/H1N1 Vaccine Antigens — 11; 12 Participants — p=0.89